Tony Hodges
Pulmonary Disease · Phoenix, AZNPI 1407883796
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $157,357 of the $247,747 with a category attached, or 63.5%. 30 manufacturers reported payments, led by Merck at 35.6% of the total. Reporting peaked in 2019 at $208,362 and has fallen 99.9% since, to $242 in 2023. Among pulmonary disease clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 552 payments — averaging $448.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$88K
- AbbVie$69K
- Tetraphase Pharmaceuticals, Inc.$27K
- Grifols USA, LLC$22K
- Insmed, Inc.$15K
- Biofire Diagnostics, LLC$8K
- plus $19K from 24 others
Across 5 payments — averaging $2762.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Shire North American Group Inc$12K
- Mayne Pharma Commercial LLC$2K
What the payments were for
- Consulting fees$16,6507%
- Speaking & faculty fees$157,35764%
- Travel & lodging$63,09525%
- Food & beverage$10,6454%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 138 | $88,201 |
| AbbVie | 201 | $69,082 |
| Tetraphase Pharmaceuticals, Inc. | 17 | $27,046 |
| Grifols USA, LLC | 39 | $21,592 |
| Insmed, Inc. | 25 | $14,708 |
| Biofire Diagnostics, LLC | 8 | $7,843 |
| Paratek Pharmaceuticals, Inc. | 10 | $5,895 |
| Genentech USA, Inc. | 17 | $4,887 |
| Mayne Pharma Commercial LLC | 6 | $2,510 |
| La Jolla Pharmaceutical Company | 6 | $2,359 |
| AstraZeneca(2 entities) | 4 | $994 |
| United Therapeutics Corporation | 16 | $957 |
| Novartis | 3 | $245 |
| Philips North America LLC | 9 | $216 |
| Actelion Pharmaceuticals US, Inc. | 7 | $213 |
| Sandoz | 4 | $210 |
| Boehringer Ingelheim | 8 | $158 |
| GSK | 7 | $103 |
| Veran Medical Technologies, Inc. | 1 | $100 |
| Electromed, Inc. | 9 | $89 |
| Boston Scientific | 1 | $77 |
| Astellas Pharma US Inc | 3 | $61 |
| Shire North American Group Inc | 3 | $50 |
| Johnson & Johnson | 3 | $33 |
| Pinnacle Biologics, Inc | 2 | $30 |
| Vapotherm Inc | 1 | $28 |
| Sanofi | 1 | $24 |
| Advanced Respiratory, Inc | 1 | $13 |
| Jazz Pharmaceuticals Inc. | 1 | $12 |
| Bayer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$247,747 in reported general payments places this provider in the 95th percentile of 250 pulmonary disease providers in Arizona.
Other pulmonary disease in Phoenix
- Rajat WaliaPhoenix$748K
- Brian PorvinPhoenix$276K
- Abid KhokarPhoenix$262K
- Mark GotfriedPhoenix$196K
- Rajeev SaggarPhoenix$161K
- Gregory AhearnPhoenix$144K
- Jagruti PatelPhoenix$141K
- Ali SaeedPhoenix$138K
- Ramit SharmaPhoenix$65K
- Bhuvin BuddhdevPhoenix$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.